CA2900949A1 - Treatment of pediatric growth hormone deficiency with human growth hormone analogues - Google Patents

Treatment of pediatric growth hormone deficiency with human growth hormone analogues Download PDF

Info

Publication number
CA2900949A1
CA2900949A1 CA2900949A CA2900949A CA2900949A1 CA 2900949 A1 CA2900949 A1 CA 2900949A1 CA 2900949 A CA2900949 A CA 2900949A CA 2900949 A CA2900949 A CA 2900949A CA 2900949 A1 CA2900949 A1 CA 2900949A1
Authority
CA
Canada
Prior art keywords
days
hgh
xten
fusion protein
bolus dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2900949A
Other languages
English (en)
French (fr)
Inventor
Jeffrey L. Cleland
George M. Bright
Eric HUMPHRISS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of CA2900949A1 publication Critical patent/CA2900949A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2900949A 2013-03-11 2014-03-10 Treatment of pediatric growth hormone deficiency with human growth hormone analogues Abandoned CA2900949A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201361776618P 2013-03-11 2013-03-11
US61/776,618 2013-03-11
US201361810786P 2013-04-11 2013-04-11
US61/810,786 2013-04-11
US201361835002P 2013-06-14 2013-06-14
US61/835,002 2013-06-14
US201361880701P 2013-09-20 2013-09-20
US61/880,701 2013-09-20
US201361911731P 2013-12-04 2013-12-04
US61/911,731 2013-12-04
US201461931987P 2014-01-27 2014-01-27
US61/931,987 2014-01-27
US201461948457P 2014-03-05 2014-03-05
US61/948,457 2014-03-05
PCT/US2014/022850 WO2014164568A1 (en) 2013-03-11 2014-03-10 Treatment of pediatric growth hormone deficiency with human growth hormone analogues

Publications (1)

Publication Number Publication Date
CA2900949A1 true CA2900949A1 (en) 2014-10-09

Family

ID=51658905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900949A Abandoned CA2900949A1 (en) 2013-03-11 2014-03-10 Treatment of pediatric growth hormone deficiency with human growth hormone analogues

Country Status (16)

Country Link
US (1) US20160158321A1 (enExample)
EP (1) EP2968451A4 (enExample)
JP (3) JP2016514132A (enExample)
KR (1) KR20150124955A (enExample)
CN (1) CN105209055A (enExample)
AU (1) AU2014249258A1 (enExample)
BR (1) BR112015022257A8 (enExample)
CA (1) CA2900949A1 (enExample)
CL (1) CL2015002456A1 (enExample)
EA (1) EA201591529A1 (enExample)
HK (1) HK1216617A1 (enExample)
IL (1) IL240392A0 (enExample)
MX (1) MX2015012175A (enExample)
PH (1) PH12015502063A1 (enExample)
SG (1) SG11201506732YA (enExample)
WO (1) WO2014164568A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2016109823A1 (en) * 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
WO2016124817A1 (en) 2015-02-03 2016-08-11 Beddit Oy Family sleep monitoring system
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
EP3416677B1 (en) 2016-02-17 2022-08-03 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
CN118105512A (zh) * 2016-08-30 2024-05-31 株式会社吉耐森 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR20260039804A (ko) 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
US11903683B2 (en) 2018-08-03 2024-02-20 Chelak Medical Solutions Inc Non-barometric determination of hemodynamic effects of cardiac arrhythmias using signals sensed by an implantable device
RU2753191C2 (ru) * 2019-09-26 2021-08-12 Федеральное государственное бюджетное учреждение науки Институт Биологии Развития им. Н.К. Кольцова Российской Академии Наук Новый рекомбинантный аналог гормона роста пролонгированного действия
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR102599111B1 (ko) * 2020-01-31 2023-11-07 울산대학교 산학협력단 인슐린유사성장인자-1 융합단백질 및 이의 용도
CN114258492A (zh) * 2020-07-22 2022-03-29 阿特纳赞塔里斯有限公司 一种通过使用马昔瑞林诊断儿科患者中生长激素缺乏症的筛选方法
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
ES2544982T3 (es) * 2009-09-02 2015-09-07 Merck Serono S.A. Método para predecir el nivel de respuesta al crecimiento
CN107320719A (zh) * 2012-06-05 2017-11-07 阿穆尼克斯运营公司 Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途

Also Published As

Publication number Publication date
BR112015022257A2 (pt) 2017-10-10
MX2015012175A (es) 2016-01-12
CL2015002456A1 (es) 2016-05-27
IL240392A0 (en) 2015-09-24
BR112015022257A8 (pt) 2018-01-23
EA201591529A1 (ru) 2016-04-29
SG11201506732YA (en) 2015-09-29
US20160158321A1 (en) 2016-06-09
JP2019056013A (ja) 2019-04-11
CN105209055A (zh) 2015-12-30
WO2014164568A1 (en) 2014-10-09
HK1216617A1 (zh) 2016-11-25
EP2968451A4 (en) 2017-01-04
JP2016514132A (ja) 2016-05-19
AU2014249258A1 (en) 2015-08-27
JP2017101074A (ja) 2017-06-08
EP2968451A1 (en) 2016-01-20
PH12015502063A1 (en) 2016-01-25
KR20150124955A (ko) 2015-11-06

Similar Documents

Publication Publication Date Title
US20160158321A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
EP2858664B1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
RU2477286C2 (ru) АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
WO2016109823A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP4026854B2 (ja) 腸栄養性glp―2ペプチドのアンタゴニスト
US10010588B2 (en) Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20120036947A (ko) 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
US20160375101A1 (en) Methods of Using Interleukin-10 for Treating Diseases and Disorders
Kanematsu-Yamaki et al. Potent body weight-lowering effect of a neuromedin U receptor 2-selective PEGylated peptide
TWI773009B (zh) 新穎之胰島素類似物及其用途
WO2014151962A1 (en) Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
US10618970B2 (en) Method of treating cancer with IL-10 and antibodies that induce ADCC
US20200000884A1 (en) Treatment of adult growth hormone deficiency with human growth hormone analogues
WO2014014819A2 (en) Methods of treating glucose metabolism disorders
WO2014014816A2 (en) Methods of treating glucose metabolism disorders
WO2013151627A1 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190312